<DOC>
	<DOCNO>NCT00503867</DOCNO>
	<brief_summary>The main purpose study determine safety toxicity treatment SIR-Spheres® patient unresectable primary liver cancer hepatocellular carcinoma ( HCC ) . Other purpose study include assessment effect treatment overall survival , length time take disease worsen , treatment affect patient 's quality life , cancer responds treatment .</brief_summary>
	<brief_title>SIR-Spheres® Treatment Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>must confirm diagnosis HCC . least 18 year age . must confirm diagnosis HCC either histological confirmation , subject exhibit vascular liver mass presence radiographically apparent cirrhosis , alphafetoprotein ( AFP ) level great 500 UI/ml . must present HCC amenable surgical resection immediate liver transplantation , optimally treatable local ablative technique radiofrequency ablation due size , extent presence cirrhosis . must present measurable disease , define least one lesion accurately measure least one dimension great equal 10 mm spiral CT scan great equal 20 mm use conventional technique ( CT , MRI ) . must present wholeliver tumor burden great equal 15 % less equal 70 % must ECOG performance status 2 less . must normal organ marrow function Exclusion criterion : Includes list contraindication SIRSpheres® exclusion criterion specific set investigational study : hepatic artery direct therapy within previous 6 month . chemotherapy within previous 4 week recover adverse event due agent administer previously Prior external hepatic radiation therapy HCC , two prior systemic chemotherapy regime HCC concomitant therapy HCC Currently receive investigational agent treatment cancer . Any extrahepatic metastasis metastatic disease find lung , bone and/or abdominal lymph node otherwise life limit . Any concurrent malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least five year . Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement . Any following contraindication angiography selective visceral catheterization : Bleeding diathesis Severe peripheral vascular disease Portal hypertension hepatofugal flow Female subject pregnant currently breastfeed . Refusal inability use effective mean contraception men woman childbearing potential . Current enrollment investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>unresectable hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>SIR-Spheres</keyword>
	<keyword>Y-90 Microspheres</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>SIRT</keyword>
	<keyword>liver cancer</keyword>
</DOC>